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Abstract
Trastuzumab is a recombinant antibody drug that is widely
used for the treatment of breast cancer. Despite encour-
aging clinical results, some cancers are primarily resistant
to trastuzumab, and a majority of those initially responding
become resistant during prolonged treatment. The mech-
anisms of trastuzumab resistance have not been fully
understood. We examined the role of antibody-dependent
cellular cytotoxicity (ADCC) using JIMT-1 cells that are
ErbB2 positive but intrinsically resistant to trastuzumab
in vitro. Unexpectedly, in experiments mimicking adjuvant
therapy of submacroscopic disease in vivo (JIMT-1 cells
inoculated s.c. in severe combined immunodeficiency
mice), trastuzumab was able to inhibit the outgrowth
of macroscopically detectable xenograft tumors for up to
5–7 weeks. The effect is likely to be mediated via ADCC
because trastuzumab-F(ab¶)2 was ineffective in this model.
Moreover, in vitro ADCC reaction of human leukocytes
was equally strong against breast cancer cells intrinsically
sensitive (SKBR-3) or resistant (JIMT-1) to trastuzumab or
even against a subline of JIMT-1 that was established from
xenograft tumors growing despite trastuzumab treatment.
These results suggest that ADCC may be the predominant
mechanism of trastuzumab action on submacroscopic
tumor spread. Thus, measuring the ADCC activity of
patient’s leukocytes against the tumor cells may be a
relevant predictor of clinical trastuzumab responsiveness
in vivo. [Mol Cancer Ther 2007;6(7):2065–72]
Introduction
Overexpression of ErbB2 (HER2), a member of the
epidermal growth factor (EGF) receptor (EGFR) family of
receptor tyrosine kinases, occurs in 20–30% of invasive
breast cancers (1–3) and is associated with poor prognosis
and rapid relapse (4). Because cancer cell growth is often
driven by highly overexpressed oncogenes, even late-stage
tumors can be successfully treated with therapies directed
against the overexpressed oncoprotein (5, 6). The finding
that some of the anti-ErbB2 antibodies can inhibit the
growth of cancer cells overexpressing ErbB2 on their
surface was a breakthrough in anticancer therapy (7) and
led to the development of trastuzumab (Herceptin), a
recombinant humanized monoclonal antibody against the
extracellular domain of ErbB2. Trastuzumab has a remark-
able antitumor effect and is currently used worldwide for
the treatment of breast cancer (8, 9). Although the
mechanisms underlying the action of trastuzumab are still
not fully understood, several molecular effects have been
observed. In vitro trastuzumab treatment leads to (a) down-
regulation of cell surface ErbB2 (10); (b) inactivation of the
mitogen-activated protein kinase and phosphoinositide-3-
kinase pathways (11, 12); (c) cell cycle arrest in G1 (13); (d)
induction of apoptosis (10); (e ) increase in HLA-I–
restricted antigen presentation of ErbB2 (14). Furthermore,
in in vivo models, trastuzumab decreased the microvessel
density of breast cancer xenografts (15).
In addition to the direct effects on cancer cells, several lines
of evidence suggested that antibody-dependent cellular
cytotoxicity (ADCC) plays an important role in the anti-
tumor activity of trastuzumab. Clynes et al. showed that the
activity of trastuzumab on breast cancer xenografts was
attenuated in knock-out mice lacking activating FcgRIII
receptors. Furthermore, the administration of trastuzumab
lacking functional FcR binding capability resulted in
similarly attenuated response in wild-type mice (16). In
addition, Spiridon et al. found that trastuzumab-F(ab¶)2
and a mixture of F(ab¶)2 fragments of three anti-ErbB2
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immunoglobulin G (IgG) exerted significantly reduced res-
ponses compared with those of trastuzumab IgG and the
mixture of the three anti-ErbB2 IgGs in mice xenografted
with trastuzumab-sensitive breast cancer cells (17).
Despite encouraging clinical results, some cancers are
primarily resistant to trastuzumab, and a majority of those
initially responding become resistant during prolonged
treatment (8, 18). The mechanisms of trastuzumab resis-
tance have not been fully elucidated. The following
mechanisms have been implicated: (a) autocrine produc-
tion of EGF-related ligands (19); (b) activation of the
insulin-like growth factor-I (IGF-I) receptor pathway (20);
(c) masking of the trastuzumab epitope by MUC4, a cell
surface sialomucin (21, 22); (d) loss of PTEN function (23);
(e) impaired ADCC reaction (24, 25).
Possible mechanisms of trastuzumab resistance have
been studied in detail using the breast cancer cell line
JIMT-1 established from the pleural metastasis of a patient
who was clinically resistant to trastuzumab. JIMT-1 cells
are resistant to trastuzumab in vitro and also in vivo , if
therapy is initiated 45 days after establishing xenografts
(26). In the current paper, we show that in spite of
trastuzumab resistance of JIMT-1 cells in vitro and their
macroscopic tumors in vivo, proliferation of these cells
inoculated s.c. into severe combined immunodeficiency
(SCID) mice is effectively inhibited for up to 5–7 weeks if
trastuzumab treatment is started immediately. Because
trastuzumab-F(ab¶)2 exerts no similar effect, the mechanism
of early-stage trastuzumab sensitivity is likely based on
ADCC.We found no difference in the in vitro ADCC activity
of human leukocytes against JIMT-1 or SKBR-3 breast
cancer cells, although the latter are intrinsically trastuzu-
mab-sensitive in vitro , suggesting that the compromised
immune response of the host or in vivo masking of the
tumor cell surface may play key roles in the development of
the trastuzumab nonresponsive phenotype.
Materials andMethods
Cells
JIMT-1, the ErbB2-positive human breast cancer cell line
was grown in Ham’s F-12/DMEM (1:1) supplemented with
10% FCS, 60 units/L insulin, and antibiotics (26). SKBR-3
and BT-474 cell lines were obtained from the American Type
Culture Collection and cultured according to specifications.
Xenograft Tumors
The SCID C.B-17 scid/scid (originated from the laborato-
ry of Fox Chase Cancer Center, Philadelphia, PA) and nu/
nmri nude mouse population (Harlan Netherland, Horst,
the Netherlands) were housed in a pathogen-free environ-
ment. Only nonleaky SCID mice with murine IgG levels
below 100 ng/mL were used in this study (27). Seven-
week-old female nude or SCID mice were given a single s.c.
injection of 5  106 JIMT-1 cells suspended in 150 AL
Hanks’ A buffer and mixed with an equal volume of
Matrigel (BD Matrigel, BD Biosciences). Tumor volumes
were derived as the product of the length, width, and
height of the tumor measured once a week with a caliper.
Trastuzumab and trastuzumab-F(ab¶)2 were given at a
dose of 5 and 25 Ag/g, respectively, by weekly i.p. injection.
The five times greater amount of administered F(ab¶)2 was
chosen based on the different half-lives of IgG and F(ab¶)2
in vivo (17). Control mice were treated with weekly i.p.
injection of 100 AL physiologic saline (saline) or rituximab
(a humanized anti-CD20 antibody) at a dose of 5 Ag/g.
Animals were euthanized by CO2 inhalation. The experi-
ments were done with the approval of the Ethical
Committee of the University of Debrecen.
Establishment of Sublines fromJIMT-1Xenografts
The JIMT-1 X and the JIMT-1 X+ cell lines were derived
from the tumor of mice treated continuously with saline
and trastuzumab, respectively. Animals were euthanized,
and the tumors were removed and cut into small pieces
with a sterile blade, washed twice with sterile PBS, and
placed in culture dishes in medium containing F-12/
DMEM (1:1) supplemented with 20% FCS, 60 units/L
insulin, and antibiotics. The medium of JIMT-1 X+ cells also
contained 10 Ag/mL trastuzumab (28). After 3 days, debris
and dead cells were removed, and the medium was
refreshed. Confluent cultures were trypsinized and split
at a ratio of 1:2, using the same medium but with only 10%
FCS. JIMT-1 X+ cells have been grown in the presence of
10 Ag/mL trastuzumab ever since the establishment of the
cell line.
Antibodies
Herceptin (trastuzumab) and Mabthera (rituximab) were
purchased from Roche Ltd. Monoclonal antibody (mAb)
against ErbB2 (erbB2-76.5 IgG1) was produced from the
supernatant of the erbB2-76.5 hybridoma (kindly provided
by Y. Yarden,Weizmann Institute of Science, Rehovot, Israel)
and purified using protein A affinity chromatography.
Conjugation of Antibodies with Fluorescent Dyes
Covalent binding of AlexaFluor 546 (Molecular Probes) to
the erbB2-76.5 antibody was carried out according to the
manufacturer’s instructions. The dye/protein labeling ratio
was f3:1.
Preparation and Testing of Trastuzumab-F(ab¶)2
Fragment
Trastuzumab IgG (20 mg) was dissolved in 20 mmol/L
acetate buffer (pH, 4.5) and dialyzed thrice into the same
buffer and concentrated using Centricon-10 tubes (Milli-
pore Corp.). Digestion was done by adding 0.5 mL
immobilized pepsin (Pierce Biotechnology) at 37jC for
6 h. The reaction was stopped by 10 mL 2 mol/L Tris-HCl
(pH, 8.2), and digested trastuzumab was filtered through a
0.22-Am Millex filter (Millipore Corp.) to remove immobi-
lized pepsin bound to agarose beads and concentrated to
1 mL using Centricon-50 tubes (Millipore Corp.). Trastu-
zumab-F(ab¶)2 fragments and undigested trastuzumab were
separated by high-performance liquid chromatography
using a column (10  800 mm) filled with Sephacryl
S-300 (Pharmacia LKB) and an eluant of 50 mmol/L
sodium phosphate (pH, 7.0). Fractions of 0.5 mL were
collected and tested using nonreducing SDS-PAGE analy-
sis. Fractions containing trastuzumab-F(ab¶)2 without con-
tamination of undigested trastuzumab were merged,
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concentrated, and stored at 20jC. The quality of trastu-
zumab-F(ab¶)2 was tested on SKBR-3 cells; trastuzumab-
F(ab¶)2 bound to the cells competed with intact trastuzumab
and bound no Fc-specific secondary antibodies (data not
shown).
In vitro Assay of Drug Sensitivity
The effects of trastuzumab and trastuzumab-F(ab¶)2 on
the growth of JIMT-1, SKBR-3, and BT-474 cells were
evaluated using the AlamarBlue method (TREK Diagnostic
Systems, Inc.). Exponentially growing cells were harvested
and plated in single wells of a 96-well flat-bottomed tissue
culture plate at defined densities, ranging from 4,500–8,000
cells per well depending on the cell line. After overnight
culture, the regular medium was exchanged to medium
containing 0, 1, 10, or 100 Ag/mL trastuzumab or
trastuzumab-F(ab¶)2. Cell viability was tested after 72 h of
treatment according to the manufacturer’s instructions.
Fluorescence was detected at an excitation of 544 nm, and
emission was detected at 590 nm using a Wallac Victor2
plate reader (Perkin-Elmer).
Immunohistochemistry
S.c. tumors were removed from anesthetized mice,
covered with Shandon Cryomatrix (Thermo Electron
Corporation, Anatomical Pathology USA Clinical Diagnos-
tics), and stored in liquid nitrogen. Cryosections, 20 Am
thick, were cut using a SHANDON AS-620E Cryotome
(Thermo Electron Corporation) on silanized slides. Samples
were fixed in 4% formaldehyde for 30 min and were
washed twice in PBS with 1% bovine serum albumin (BSA;
pH, 7.4) for 20 min at room temperature. Slides were
labeled with a saturating concentration (10–20 Ag/mL) of
dye-conjugated antibody in 100 AL PBS containing 1% BSA
overnight on ice, washed twice with PBS, and covered with
15 AL Mowiol (Merck) to avoid bleaching of the fluorescent
dyes.
Confocal Microscopy
A Zeiss LSM 510 confocal laser-scanning microscope
(Carl Zeiss AG) was used to image samples. AlexaFluor 546
was excited with the 543-nm line of a green He-Ne laser,
and emission measured between 560 and 615 nm. Fluores-
cence images were taken as 1-Am optical sections using a
63 (numerical aperature = 1.4) oil immersion objective.
ImageAnalysis
Confocal microscopic images were analyzed with the
DipImage toolbox (Delft University of Technology, Delft,
the Netherlands) under Matlab (Mathworks Inc., Natick,
MA). The cell membrane was identified by a manually
seeded watershed algorithm (29) using a custom-written
interactive algorithm implemented in DipImage/Matlab.
The cell membrane was used as a mask, and the
fluorescence intensity was evaluated only in pixels under
the mask.
In vitro ADCCAssay
ADCC assays were done as described previously (17, 30)
with modifications. Peripheral blood mononuclear cells
(PBMC) were separated from the blood of healthy donors
by Ficoll density gradient centrifugation (Histopaque-1077,
Sigma-Aldrich). The fraction containing PBMCs was
resuspended in DMEM containing 10% FCS. JIMT-1, JIMT
X, JIMT X+, and SKBR-3 tumor cells were harvested,
washed once in PBS containing 1% bovine serum albumin
(BSA), and labeled with 5- (and 6)-carboxyfluorescein
Figure 1. A, trastuzumab partially inhibits growth of established early-
stage JIMT-1 xenograft tumors in SCID mice. About 5  106 JIMT-1 cells
were injected s.c. into SCID mice, and weekly treatment (arrows ) with
trastuzumab (o) or saline (.) was initiated 9 d after tumor inoculation,
when the tumors were palpable (n = 8 in both groups). Tumor growth
was significantly reduced in the trastuzumab-treated group versus the
control group between days 16 and 44. *, P < 0.05. B, trastuzumab
inhibits outgrowth of JIMT-1 tumors in nude mice. Trastuzumab (o, n =
7) or rituximab (., n = 7) treatment of nude mice injected with 5  106
tumor cells was started on the day of tumor cell inoculation and continued
on a weekly basis (arrows ). Trastuzumab therapy was suspended on day
42. Tumor growth was significantly reduced in the trastuzumab-treated
group versus the control group between days 21 and 56. *, P < 0.05. C,
trastuzumab markedly hinders early tumor outgrowth from JIMT-1 cells
inoculated in SCID mice. Trastuzumab (o, n = 8) or saline (., n = 8)
treatment (arrows ) of mice injected with 5  106 tumor cells was started
on the day of tumor cell inoculation and continued on a weekly basis. In
four out of the eight trastuzumab-treated mice, trastuzumab administra-
tion was suspended (!) on week 9 (marked by ), whereas it was
continued for another 6 wks in the other four (4). Tumor growth was
significantly reduced in the trastuzumab-treated group versus the control
group between days 14 and 91. *, P < 0.05. There was no significantly
difference between the ‘‘suspended trastuzumab’’ and ‘‘continued
trastuzumab’’ subgroups. Note that tumor volumes are plotted on different
scales.
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diacetate, succinimidyl ester (CFDA, SE; Molecular Probes,
Inc.) at a concentration of 10 Amol/L at 37jC for 10 min.
Then, tumor cells were washed thrice with DMEM
containing 10% FCS and 1% BSA to remove unreacted
and unbound CFDA, SE. Between the washing steps, cells
were incubated in the same medium at 37jC for 5 min.
Finally, the labeled target cells were resuspended in DMEM
containing 10% FCS and mixed with PBMCs at effector/
target ratios (E/T) of 2:1, 6:1, 15:1, 30:1, and 60:1.
Trastuzumab, rituximab, or trastuzumab-F(ab¶)2 were
added to the mixed suspensions at a concentration
100 Ag/mL. The samples were incubated at 37jC for 8 h
followed by staining of dead cells with 50 Ag/mL
propidium iodide. Cells were analyzed on a Becton
Dickinson FACScan flow cytometer (Mountain View). The
negative control sample was prepared identically, but did
not contain PBMCs. Tumor cells killed by 4% formalde-
hyde served as the positive control. The percentage of cells
killed was calculated according the following formula:
(% of living cells in the negative control  % of living cells
in the sample) /% of living cells in the negative control.
Statistical Analysis
Data are expressed as the mean F SE. The statistical
significance of the differences between means were
determined using Student’s t test for two samples after
verifying that data passed the normality test and the
groups compared have equal variance. Differences were
statistically significant at P < 0.05.
Results
Effect of Trastuzumab on Established JIMT-1 Xeno-
graft Tumors
We have shown previously that established JIMT-1
xenograft tumors (tumor volume 200–500 mm3) are
insensitive to trastuzumab treatment in immunodeficient
nu/nmri mice (26). First, we tested the effects of trastuzu-
mab on smaller xenograft tumors of 100–200 mm3 volume
in SCID mice that had been inoculated s.c. with 5  106
JIMT-1 cells in suspension only 9 days before treatment.
Weekly treatment with trastuzumab or saline was contin-
ued until the end of the experiment. Tumor growth was
partially but significantly inhibited by trastuzumab from
days 16 to 44 (P < 0.05) when compared with the control
group (Fig. 1A).
Effect of Trastuzumab on Nonestablished JIMT-1
Tumors in Nude or SCIDMice
Because the growth of small JIMT-1 xenograft tumors
was partially inhibited by trastuzumab, we next studied the
effect of trastuzumab treatment started at the time when
5  106 JIMT-1 cells were inoculated s.c. into nude or SCID
mice.
Tumors were formed in all of the seven nude mice
treated with rituximab (a negative control antibody
directed to CD20, a transmembrane protein not expressed
by JIMT-1 cells; data not shown), whereas palpable tumors
developed only in two of seven trastuzumab-treated
animals. Trastuzumab administration was suspended on
day 42 when the inhibitory effect of trastuzumab was
obvious as compared with rituximab treatment. Trastuzu-
mab had a significant inhibitory effect on tumor growth
from days 21 to 56 (P < 0.05). After stopping trastuzumab
administration, tumors started to grow in the two nude
mice whose tumors were palpable earlier (Fig. 1B).
The growth of tumors in all trastuzumab-treated SCID
mice was minimal for up day 42. From the fifth week
onward, the tumors started to grow exponentially in all
(8/8) trastuzumab-treated mice. At this time point,
trastuzumab treatment was suspended in half of the
treated animals and continued for another 6 weeks in the
rest of the animals. There was no difference in the rate of
Figure 2. In vitro and in vivo effects of trastuzumab-F(ab¶)2. A,
trastuzumab-F(ab¶)2 acts in vitro similar to whole trastuzumab. Trastuzu-
mab-F(ab¶)2 inhibited the growth of trastuzumab-sensitive cell lines SKBR-
3 and BT-474 in vitro as effectively as trastuzumab IgG. JIMT-1 cells were
resistant in vitro to both trastuzumab-IgG and trastuzumab-F(ab¶)2. T,
trastuzumab; TF, trastuzumab-F(ab¶)2. Doses: black column, 1 Ag/mL;
cross-hatched column, 10 Ag/mL; hatched column, 100 Ag/mL. Neither
trastuzumab whole IgG nor trastuzumab-F(ab¶)2 fragment had any
inhibitory effect on JIMT-1 cells in vitro , whereas both had significant
inhibitory effect on SKBR-3 and BT-474 cells as compared with their effect
on JIMT-1 cells. *, P < 0.05. B, lack of effect of trastuzumab-F(ab¶)2 on
JIMT-1 xenografts. SCID mice injected s.c. with 5  106 JIMT-1 cells were
treated i.p. on a weekly basis (arrows ) with saline (., n =8), trastuzumab
IgG (o, n = 8), or trastuzumab-F(ab¶)2 (!, n = 8), starting on the day of
inoculation. Tumor growth was significantly reduced in the trastuzumab-
treated group versus the saline-treated group between days 14 and 42. *,
P < 0.05. There was no significant difference between the trastuzumab-
F(ab¶)2 and the saline-treated groups.
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tumor growth between these two subgroups, indicating
complete resistance to trastuzumab (Fig. 1C). The effect of
trastuzumab on tumor growth was significant from days
14 to 91 (P < 0.05).
TreatmentofJIMT-1TumorswithTrastuzumab-F(ab¶)2
Because JIMT-1 cells are intrinsically resistant to trastu-
zumab, we hypothesized that the effects on submacro-
scopic xenografts are owed to ADCC reaction. We have
therefore generated trastuzumab-F(ab¶)2, which binds
ErbB2 with high affinity and exhibits in vitro growth
inhibition equivalent to that of intact trastuzumab IgG in
both SKBR-3 and BT-474 cell cultures (Fig. 2A). When
using this trastuzumab-F(ab¶)2 for weekly treatment of
SCID mice inoculated with 5  106 JIMT-1 cells, on a
weekly basis, no effect on xenograft tumor growth was
seen as compared with saline treatment. In the parallel
positive control, intact trastuzumab IgG significantly
inhibited the growth of JIMT-1 tumors (from days 14 to
42; P < 0.05) similarly to findings in the previous
experiment (Fig. 2B).
Cell Surface Expression Level of ErbB2 in JIMT-1
Xenografts
To investigate whether trastuzumab IgG and trastuzu-
mab-F(ab¶)2 were able to down-regulate ErbB2 in vivo, fast
frozen tissue sections were labeled with a fluorescent anti-
ErbB2 antibody erbB2-76.5. The ErbB2 expression level of
trastuzumab-treated tumors was f50% lower than that of
saline-treated cells. Quantitative image analysis revealed
that trastuzumab-F(ab¶)2 and trastuzumab IgG were equally
effective in down-regulating ErbB2 expression. Six weeks
after suspension of trastuzumab treatment, the ErbB2
expression level returned to almost as high as in control
mice (Fig. 3A and B).
In vitro ADCCActivity against Trastuzumab-Sensitive
andTrastuzumab-Resistant Breast Cancer Cell Lines
The fact that trastuzumab-F(ab¶)2, unlike trastuzumab
IgG, was ineffective against JIMT-1 xenografts in vivo
suggested that the immune effector cells of SCID mice are
responsible for growth retardation, irrespective of intrinsic
cellular resistance. We next did in vitro ADCC assays using
human peripheral leukocytes (PBMCs) as effector cells. The
baseline killing of tumor target cells by PBMCs in the
presence of rituximab (IgG control) was low; there was no
significant difference in target cell killing between assays
done with rituximab or with trastuzumab-F(ab¶)2. In
contrast, the presence of trastuzumab IgG significantly
increased killing of all breast cancer cell lines (P < 0.05). The
ADCC activity of PBMCs evoked by trastuzumab was
equally strong against trastuzumab-sensitive (SKBR-3) or
trastuzumab-resistant (JIMT-1) breast cancer cells, with
dose-dependent cell death reaching f50–60% killing at
an effector/target ratio of 60:1. In addition to the native
JIMT-1 cells, two sublines, JIMT-1 X, recovered from
xenografted mice treated with saline, and JIMT-1 X+, a
superresistant subline recovered after continuous treatment
with trastuzumab, were as sensitive to ADCC as SKBR-3
(Fig. 4).
Discussion
It is well documented that trastuzumab acts directly in
cancer cell signaling, as well as indirectly via the immune
system. We studied the in vivo effects of trastuzumab using
JIMT-1 cells that are intrinsically resistant to trastuzumab
in vitro , despite ErbB2 gene amplification and receptor
Figure 3. Changes in ErbB2 level after trastuzumab IgG and trastuzu-
mab-F(ab¶)2 treatment. A, immunofluorescent images of frozen sections
prepared from JIMT-1 xenografts. Mice were treated with saline (top left ),
trastuzumab-F(ab¶)2 (top right ), trastuzumab IgG continuously (bottom
left ), or trastuzumab IgG suspended 6 weeks before sacrificing the animal
(bottom right ). ErbB2 was labeled with AlexaFluor 543–conjugated
erbB2-76.5 antibodies. Images were taken with identical microscope
settings. B, quantitative analysis of membrane fluorescence. Five images
from each type of treatment were analyzed as described in Materials and
Methods, and the average fluorescence intensity registered in membranes
was plotted. Black column, saline; cross-hatched column, continuous
trastuzumab IgG; empty column, suspended trastuzumab IgG; hatched
column, continuous trastuzumab-F(ab¶)2. Continuous trastuzumab IgG
and trastuzumab-F(ab¶)2 treatment decreased ErbB2 levels significantly. *,
P < 0.05.
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overexpression. The JIMT-1 cell line is a unique patient-
derived model system, which allows for separately
studying the direct and immune-mediated growth-inhibi-
tory mechanisms of trastuzumab when using in vitro and
xenograft models (26).
Our main and unexpected finding was that trastuzumab
caused a significant growth inhibition of the outgrowth of
macroscopic JIMT-1 xenograft tumors in both nude and
SCID mice. The effect was probably mediated via the Fc
portion of trastuzumab IgG because the F(ab¶)2 fragment of
trastuzumab was ineffective in the SCID mouse model
system, in spite of inhibiting proliferation of trastuzumab-
sensitive cells in vitro equally well as intact trastuzumab
IgG. We attribute the Fc-mediated effects of trastuzumab to
ADCC because both nude and SCID mice have functioning
macrophages and natural killer cells (31–33) capable of
killing tumor cells by ADCC. The antitumor effect of
trastuzumab was stronger in nude mice because it
prevented the formation of palpable tumors in five out of
seven nude mice, whereas it only slowed the growth rate of
JIMT-1 xenografts in SCID mice. This phenomenon can be
explained by the more severe immunodeficiency of SCID
mice lacking both T and B cells (31) compared with nude
mice capable of mounting a B cell response against thymus-
independent antigens (34, 35). These findings reflect the
central role of the immune system in mediating the effects
of trastuzumab in vivo . In a previous study, Clynes et al.
inoculated trastuzumab-sensitive BT-474 cells into knock-
out mice lacking activating FcRgIII receptors. In this model
system, the antitumor activity of trastuzumab was reduced
but not ablated: about 25% of the effect was retained (16). In
the same manner, treatment of wild-type mice with the
mutated form of 4D5, the parent antibody of trastuzumab,
which was made unable to bind to Fc receptors, had a
similar partial effect (16). These results indicate that in the
case of BT-474 cells, trastuzumab probably triggers both the
intrinsic growth-inhibitory and apoptotic regulatory path-
ways, as well as evokes ADCC. In the case of the
intrinsically resistant JIMT-1 cells, the mechanism of action
of trastuzumab seems to be exclusively ADCC.
The mutual independence of the intrinsic and immune-
mediated effects was further evidenced by in vitro ADCC
experiments using human peripheral leukocytes as effector
cells. The capacity of these cells to kill JIMT-1 and SKBR-3
cells in the presence of trastuzumab by ADCC was the
same despite significant differences in the direct drug-
sensitivity assays. Moreover, we found that the down-
modulation of ErbB2 receptor from the cell surface upon
trastuzumab treatment, which has previously been postu-
lated as the central phenomenon for direct growth
inhibition, (10, 36) seems to be mechanistically unrelated
to the action of trastuzumab in vivo .
The other main finding in our study was that the capacity
of the ADCC reaction to inhibit growth of xenograft tumors
was clearly dependent on tumor cell load and possibly also
the accessibility of tumor cells to effectors. Whereas s.c.
Figure 4. In vitro trastuzumab-mediated ADCC
against ErbB2-positive tumor cells. Target tumor
cells [(A) JIMT-1; (B) JIMT-1 X; (C) SKBR-3; (D)
JIMT-1 X+] were labeled with CFDA, SE, then
mixed with PBMCs freshly isolated from peripheral
blood at effector/target ratios of 2:1, 6:1, 15:1,
30:1, and 60:1. Trastuzumab (.), trastuzumab-
F(ab¶)2 (!), or rituximab (o) were added to the
mixed samples at a concentration of 100 Ag/mL.
After an 8-h incubation at 37jC, samples were
stained with propidium iodide and analyzed by flow
cytometry. The percentage of killed cells was
calculated as described in Materials and Methods.
In all cell lines, tumor cell killing was significantly
higher in the presence of trastuzumab whole IgG
than that observed in the presence of trastuzumab-
F(ab¶)2 fragment when the effector/target cell ratio
was 15 or above. *, P < 0.05. No significant
difference was observed between the effects of
rituximab and trastuzumab-F(ab¶)2. Similarly, no
significant differences were observed among the
cell lines in the killing effect of trastuzumab-
mediated ADCC.
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inoculated JIMT-1 cells were initially sensitive to trastuzu-
mab, this sensitivity was gradually lost as the tumors grew
larger in size. These results contrast those published for
intrinsically trastuzumab-sensitive BT-474 xenografts,
where trastuzumab treatment is highly effective also in
the case of larger established tumors (17, 37).
Theoretically, it is possible that JIMT-1 xenografts had
acquired new resistance mechanisms against ADCC during
trastuzumab treatment. However, we find this unlikely
because the subline JIMT-X+, generated from a trastuzu-
mab-treated JIMT-1 xenograft, did not differ from the
parental JIMT-1 cells in the in vitro ADCC assays. JIMT-1
X+ cells were able to form xenografts in SCID mice, and the
growth of the xenografts was reduced by trastuzumab
administration, suggesting that JIMT-1 X+ cells were
initially sensitive to trastuzumab also in vivo , although
trastuzumab resistance has developed after 3 weeks (data
not shown). Thus, it is more likely that in SCID mice, the
capacity for ADCC is gradually exhausted with increasing
tumor load. These results are coherent with recent clinical
observations indicating a surprisingly high efficacy of
adjuvant trastuzumab therapy applied at early stages of
the tumor, compared with less striking results achieved in
overtly metastatic disease (38–40). If the clinical effects of
trastuzumab on submacroscopic disease are mainly de-
rived from ADCC, which, based on the present observa-
tions, seems to lose its efficacy as the tumor grows, it is
possible that clinical benefits may decrease during extend-
ed follow-up.
Finally, our results may have important implications in
the search for putative trastuzumab resistance mecha-
nisms. Many groups, including ours, have characterized
breast cancer cell lines and clinical tumor specimens for
intrinsic cellular features such as ErbB2 protein turnover,
autocrine production of EGF-related ligands (19), activa-
tion of the IGF-I receptor pathway (20), loss of PTEN
function (23), steric hindrance of ErbB2 on the cell surface
(22, 41). Although these intrinsic mechanisms may partly
underlie nonresponsiveness to trastuzumab, our results
clearly stress the importance of immune-mediated mech-
anisms, the capacity of which may vary depending on
tumor volume, either as a function of gross cell numbers,
or of accessibility of tumor cells by effector cells. In the
clinical setting, the importance of immune mechanisms
has been highlighted by Gennari et al. (42), who have
showed that the only statistically significant difference
between trastuzumab-responding and nonresponding
patients was in the ADCC activity of peripheral blood
leukocytes. Unfortunately, currently available ADCC assays
are technically too complicated for routine clinical diag-
nostics. Thus, the development of simpler ADCC assays or
new surrogate markers (such as FcgRIIIa gene polymor-
phisms; ref. 43) may be of significant help in optimal patient
selection for trastuzumab therapy. In the future, new
approaches such as anti-ErbB2 antibodies engineered for
higher affinity Fc receptor binding may also lead to
improved therapeutic efficacy of ErbB2-positive breast
cancers (44).
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